Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP3 | O60896 | 12/20 | 0.57 |
| ▸ | CALCR | P30988 | 12/20 | 0.57 |
| ▸ | EP300 | Q09472 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 6/20 | 0.54 |
| ▸ | NPY4R | P50391 | 6/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.54 |
| ▸ | NPY1R | P25929 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30429234 | 0.88 | EP300 (0.62) | RAMP3CALCREP300HIF1ANPY2R | |
| SCHEMBL30432226 | 0.88 | EP300 (0.62) | RAMP3CALCREP300HIF1ANPY2R | |
| SCHEMBL30423163 | 0.87 | RAMP3 (0.60) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30495643 | 0.87 | NPY2R (0.63) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL29949632 | 0.87 | MAPK8 (0.59) | RAMP3CALCREP300HIF1ANPY2R | |
| SCHEMBL31683337 | 0.87 | NPY2R (0.61) | RAMP3CALCREP300HIF1ANPY2R | |
| SCHEMBL29479782 | 0.87 | EP300 (0.60) | RAMP3CALCREP300HIF1ANPY2R | |
| SCHEMBL31182942 | 0.87 | NPY2R (0.59) | RAMP3CALCREP300HIF1ANPY2R | |
| SCHEMBL30648440 | 0.86 | RAMP3 (0.65) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL29949435 | 0.86 | NPY2R (0.58) | RAMP3CALCREP300HIF1ANPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102434-A1 | HIGH-PERFORMANCE MATURE INTESTINAL ORGANOID REGENERATIVE THERAPEUTIC AGENT DERIVED FROM PLURIPOTENT STEM CELLS | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2026-04-16 | — | — | US | claimed |
| US-20250345391-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEPSIS | CHILDRENS HOSPITAL MED CT (US) | 2025-11-13 | — | — | US | claimed |
| WO-2025230907-A1 | A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-06 | — | — | WO | claimed |
| EP-4600349-A1 | STROMAL CELL LAYER AROUND INTESTINAL ORGANOID FOR ENHANCING ENGRAFTMENT AND REGENERATION EFFICACY, AND USE THEREOF | Korea Research Institute of Bioscience and Biotechnology (KR) | 2025-08-13 | — | — | EP | claimed |
| EP-4592382-A1 | HIGH-PERFORMANCE MATURE INTESTINAL ORGANOID REGENERATIVE THERAPEUTIC AGENT DERIVED FROM PLURIPOTENT STEM CELLS | Korea Research Institute of Bioscience and Biotechnology (KR) | 2025-07-30 | — | — | EP | claimed |
| US-20250215397-A1 | TWO-DIMENSIONAL CULTURE METHOD HAVING CLEAR CHEMICAL COMPOSITION FOR CULTURING THREE-DIMENSIONAL INTESTINAL ORGANOID-DERIVED INTESTINAL STEM CELL AGGREGATE | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2025-07-03 | — | — | US | claimed |
| US-20250205337-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS | MDX MAN LLC (US) | 2025-06-26 | — | — | US | claimed |
| WO-2025038745-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS | MDX MANAGEMENT LLC (US) | 2025-02-20 | — | — | WO | claimed |
| EP-4499117-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS | MDX Management LLC (US) | 2025-02-05 | — | — | EP | claimed |
| US-20240415868-A1 | COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE | AXOLABS GMBH (DE) | 2024-12-19 | — | — | US | claimed |
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | KEEFER, Edward (US) | 2024-08-29 | — | — | US | claimed |
| WO-2023192542-A9 | COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS | MDX MANAGEMENT LLC (US) | 2024-08-15 | — | — | WO | claimed |
| US-11969522-B2 | Use of immune modulators to improve nerve regeneration | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-30 | — | — | US | claimed |
| US-11951121-B2 | Compositions and methods for treating Huntington's disease | VOYAGER THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | claimed |
| WO-2024063531-A1 | STROMAL CELL LAYER AROUND INTESTINAL ORGANOID FOR ENHANCING ENGRAFTMENT AND REGENERATION EFFICACY, AND USE THEREOF | 한국생명공학연구원 | 2024-03-28 | — | — | WO | claimed |
| WO-2023235553-A1 | HUMANIN, COLIVELIN AND DERIVATIVES FOR THE TREATMENT OF HEMORRHAGIC SHOCK | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-12-07 | — | — | WO | claimed |
| WO-2023192542-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS | MDX MANAGEMENT LLC (US) | 2023-10-05 | — | — | WO | claimed |
| CN-109831916-B | Compositions and methods for treating huntington's disease | 沃雅戈治疗公司 | 2023-07-21 | — | — | CN | claimed |
| CN-122029273-A | Compositions and methods for activating immune cells | MDX管理有限责任公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-114099681-A | Use of AKT/STAT3 as target for immune checkpoint inhibitors | 周清华 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102434-A1 | HIGH-PERFORMANCE MATURE INTESTINAL ORGANOID REGENERATIVE THERAPEUTIC AGENT DERIVED FROM PLURIPOTENT STEM CELLS | MYLK, MYLK2, DSP | RAMP3 2625/4885CALCR 3435/4885EP300 2078/4885 |
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | CXCR3, CXCL12, CXCR4 | RAMP3 559/4885CALCR 330/4885EP300 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.